Vigil Neuroscience company info

What does Vigil Neuroscience do?
Vigil Neuroscience (NASDAQ:VIGL) is dedicated to tackling neurodegenerative diseases by understanding and leveraging the power of microglia, the brain's primary immune cells. Their focused approach aims to develop treatments that can modify disease progression in conditions such as Alzheimer's and Amyotrophic Lateral Sclerosis (ALS). With a deep commitment to innovation, Vigil Neuroscience embarks on projects that explore the potential of microglial restoration and protection. The company's objective is to bring forth novel therapies that can significantly improve the lives of patients suffering from these debilitating diseases, providing hope through scientific advancement and dedicated research.
Vigil Neuroscience company media
Company Snapshot

Is Vigil Neuroscience a public or private company?


How many people does Vigil Neuroscience employ?


What sector is Vigil Neuroscience in?

pie chart
Health Care

Where is the head office for Vigil Neuroscience?

location pin
Head Office
Watertown, United States

What year was Vigil Neuroscience founded?

founded flag
Year Founded
What does Vigil Neuroscience specialise in?
/Neurodegenerative Diseases /Drug Development /Genetic Testing /Genetic Neurological Disorders /Research & Development /Clinical Trials

What are the products and/or services of Vigil Neuroscience?

Overview of Vigil Neuroscience offerings
Trem2 Agonists targeting Alzheimer's disease and other neurodegenerative disorders.
Antibody-based therapies for microglial restoration in central nervous system diseases.
Small molecule inhibitors for neuroinflammatory and neurodegenerative conditions.
Gene therapy approaches for the treatment of rare neurological diseases.
Biomarker identification and diagnostics development for neurodegenerative diseases.
Collaborative research programs with academic and industry partners for novel therapeutic discovery.

Who is in the executive team of Vigil Neuroscience?

Vigil Neuroscience leadership team
  • Dr. Ivana  Magovcevic-Liebisch J.D., Ph.D.
    Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
    President, CEO & Director
  • Ms. Jennifer  Ziolkowski CPA
    Ms. Jennifer Ziolkowski CPA
    Chief Financial Officer
  • Sharon  Morani
    Sharon Morani
    Senior Director of Facilities & Operations
  • Dr. David  Gray Ph.D.
    Dr. David Gray Ph.D.
    Chief Scientific Officer
  • Ms. Leah  Gibson
    Ms. Leah Gibson
    Vice President of Investor Relations and Corporate Communications
  • Mr. Christopher  Verni J.D.
    Mr. Christopher Verni J.D.
    General Counsel & Corporate Secretary
  • April  Effort M.B.A., M.S.
    April Effort M.B.A., M.S.
    VP & Head of Corporate Development
  • Mr. Evan A. Thackaberry DABT, Ph.D.
    Mr. Evan A. Thackaberry DABT, Ph.D.
    Senior VP & Head of Early Development